These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1214 related articles for article (PubMed ID: 33711225)

  • 41. Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity.
    Lee N; Jeong S; Park MJ; Song W
    PLoS One; 2021; 16(6):e0253889. PubMed ID: 34185813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.
    National SARS-CoV-2 Serology Assay Evaluation Group
    Lancet Infect Dis; 2020 Dec; 20(12):1390-1400. PubMed ID: 32979318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay.
    Pieri M; Nuccetelli M; Nicolai E; Sarubbi S; Grelli S; Bernardini S
    J Med Virol; 2021 Apr; 93(4):2523-2528. PubMed ID: 33463719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.
    Meschi S; Colavita F; Bordi L; Matusali G; Lapa D; Amendola A; Vairo F; Ippolito G; Capobianchi MR; Castilletti C;
    J Clin Virol; 2020 Aug; 129():104539. PubMed ID: 32679298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analytical and Clinical Analysis of Two Automated Anti-SARS-CoV-2 Immunoassays in Pre-Pandemic and Pandemic Patient Populations.
    Yang J; Pederson EC; Hamilton C; Neibauer T; Robyak K; McGhee P; Speicher T; Zhu Y
    J Appl Lab Med; 2021 Mar; 6(2):441-450. PubMed ID: 33152084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.
    Patel EU; Bloch EM; Clarke W; Hsieh YH; Boon D; Eby Y; Fernandez RE; Baker OR; Keruly M; Kirby CS; Klock E; Littlefield K; Miller J; Schmidt HA; Sullivan P; Piwowar-Manning E; Shrestha R; Redd AD; Rothman RE; Sullivan D; Shoham S; Casadevall A; Quinn TC; Pekosz A; Tobian AAR; Laeyendecker O
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139419
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
    Tré-Hardy M; Wilmet A; Beukinga I; Favresse J; Dogné JM; Douxfils J; Blairon L
    J Med Virol; 2021 Feb; 93(2):803-811. PubMed ID: 32667733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
    Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
    Front Immunol; 2020; 11():609242. PubMed ID: 33424863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal Assessment of SARS-CoV-2 Antinucleocapsid and Antispike-1-RBD Antibody Testing Following PCR-Detected SARS-CoV-2 Infection.
    El-Khoury JM; Schulz WL; Durant TJS
    J Appl Lab Med; 2021 Jul; 6(4):1005-1011. PubMed ID: 33822964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests.
    Péré H; Mboumba Bouassa RS; Tonen-Wolyec S; Podglajen I; Veyer D; Bélec L
    J Virol Methods; 2021 Apr; 290():114067. PubMed ID: 33476707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Performance evaluation of an automated SARS-CoV-2 Ag test for the diagnosis of COVID-19 infection on nasopharyngeal swabs.
    Hartard C; Berger S; Josse T; Schvoerer E; Jeulin H
    Clin Chem Lab Med; 2021 Nov; 59(12):2003-2009. PubMed ID: 34331847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2.
    Wu JL; Tseng WP; Lin CH; Lee TF; Chung MY; Huang CH; Chen SY; Hsueh PR; Chen SC
    J Infect; 2020 Sep; 81(3):435-442. PubMed ID: 32553841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System.
    Angeloni S; Cameron A; Pecora ND; Dunbar S
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33900295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel.
    Mboumba Bouassa RS; Péré H; Tonen-Wolyec S; Longo JD; Moussa S; Mbopi-Keou FX; Mossoro-Kpinde CD; Grésenguet G; Veyer D; Bélec L
    J Med Virol; 2021 Apr; 93(4):2196-2203. PubMed ID: 33107601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies.
    Montesinos I; Gruson D; Kabamba B; Dahma H; Van den Wijngaert S; Reza S; Carbone V; Vandenberg O; Gulbis B; Wolff F; Rodriguez-Villalobos H
    J Clin Virol; 2020 Jul; 128():104413. PubMed ID: 32403010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19.
    Du J; Chu E; Zhang D; Lu CM; Zhang A; Sha MY
    J Virol Methods; 2021 Jan; 287():114009. PubMed ID: 33152411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of three automatic chemiluminescent immunoassays for monitoring dynamic profile of SARS-CoV-2 IgG and IgM.
    Dou X; Wang E; Hu J; Zong Z; Jiang R; Wang M; Kan L; Zhang X
    J Clin Lab Anal; 2021 Jan; 35(1):e23681. PubMed ID: 33340166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays.
    Qian C; Zhou M; Cheng F; Lin X; Gong Y; Xie X; Li P; Li Z; Zhang P; Liu Z; Hu F; Wang Y; Li Q; Zhu Y; Duan G; Xing Y; Song H; Xu W; Liu BF; Xia F
    Clin Chem Lab Med; 2020 Aug; 58(9):1601-1607. PubMed ID: 32609640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins.
    Bray RA; Lee JH; Brescia P; Kumar D; Nong T; Shih R; Woodle ES; Maltzman JS; Gebel HM
    Transplantation; 2021 Jan; 105(1):79-89. PubMed ID: 33273320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.